TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24588932

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (6 different probiotic strains; 10^9 cfu/g) for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (5 g sachet per day for 6 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23214314

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray combined with Hydrochloric acid left Kabbah Sting nasal spray
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Health education management and lifestyle intervention (on the basis of group B's therapy)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 210
Study: 20713677

Group type: EXPERIMENTAL
Intervention: darunavir-ritonavir mono- or tritherapy
Number of subjects: 45
Study: 18162699

Group type: EXPERIMENTAL
Intervention: fMRI study of covert verb generation (VG) in children with TBI
Number of subjects: 8

Group type: COMPARATOR
Intervention: fMRI study of covert verb generation (VG) in children with orthopedic injuries (OI)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BOLD signal activation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Conventional MR images
Number of subjects: 8
Study: 16885042

Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg/d
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15234671

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 0
Study: 11020745

Group type: EXPERIMENTAL
Intervention: Oral clonidine 4 microg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epinephrine test dose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Isoproterenol test dose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epinephrine or isoproterenol
Number of subjects: 120
Study: 9273233

Group type: EXPERIMENTAL
Intervention: Sclerodermic children
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 34
Study: 1510286

Group type: EXPERIMENTAL
Intervention: 10 mg astemizole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg astemizole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6426893

Group type: EXPERIMENTAL
Intervention: Early postoperative enteral feeding via fine bore feeding tube (carbohydrates, fat, short-chain peptides)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard intravenous fluids (carbohydrates and amino acids)
Number of subjects: 40
Study: 31061014

Group type: EXPERIMENTAL
Intervention: Experimental treatment (psychosocial intervention administered by speech and language therapists)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study: 28284834

Group type: EXPERIMENTAL
Intervention: 3-month active cycling group (ACG, n=33)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (CG, n=26)
Number of subjects: 59
Study: 25886587

Group type: EXPERIMENTAL
Intervention: Community-based worker intervention involving home visits and women's group meetings
Number of subjects: 2520

Group type: COMPARATOR
Intervention: Control group receiving support to Village Health Sanitation and Nutrition Committees only
Number of subjects: 2520
Study: 23984830

Group type: EXPERIMENTAL
Intervention: Pharmacist-acquired medication history
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 270
Study: 21242364

Group type: EXPERIMENTAL
Intervention: Interactive storytelling intervention using 3 DVDs containing patient stories.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Attention control DVD.
Number of subjects: 230
Study: 19602031

Group type: EXPERIMENTAL
Intervention: Transthoracic cardioversion performed within 30 days after recurrence of atrial arrhythmia
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Transthoracic cardioversion performed after recurrence of atrial arrhythmia
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Time to cardioversion within 30 days after onset of atrial arrhythmia
Number of subjects: 384
Study: 16882684

Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine 8% spray
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline placebo spray
Number of subjects: 25
Study: 15273642

Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 30
Study: 11512528

Group type: EXPERIMENTAL
Intervention: clarithromycin MR 500 mg once daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: amoxicillin/clavulanic acid 500 mg/125 mg three times daily
Number of subjects: 250
Study: 9023466

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 or 50 mg)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 8112370

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg oral dose)
Number of subjects: 8
Study: 3090845

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both anaesthetic techniques
Number of subjects: 42
Study: 30048473

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure for 8 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) for 8 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combined Training (CT) for 8 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control period (no training) for 8 weeks
Number of subjects: 37
Study: 27318221

Group type: EXPERIMENTAL
Intervention: CBT‐I + P
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CBT‐I + A
Number of subjects: 88

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 88

Group type: COMPARATOR
Intervention: ARM
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study: 25186800

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study: 22349455

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control arm
Number of subjects: 0
Study: 20644020

Group type: EXPERIMENTAL
Intervention: V(1) ST elevation >or=1 mm
Number of subjects: 7967

Group type: EXPERIMENTAL
Intervention: Persistence of V(1) ST elevation >or=1 mm 60 minutes after fibrinolysis
Number of subjects: 7967

Group type: EXPERIMENTAL
Intervention: V(1) ST elevation analyzed as a continuous variable
Number of subjects: 7967

Group type: EXPERIMENTAL
Intervention: V(1) ST depression
Number of subjects: 7967
Study: 18661769

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 mg/kg) along with DTP vaccine
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 mg/kg) 2 hours after vaccination
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (acetaminophen after febrile reactions or irritability)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study: 16191138

Group type: EXPERIMENTAL
Intervention: Patient reminders
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Computer reminders
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both reminders
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study: 12369652

Group type: EXPERIMENTAL
Intervention: Pneumococcus vaccination
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 9845865

Group type: EXPERIMENTAL
Intervention: Inpatient and residential programs
Number of subjects: 2966

Group type: EXPERIMENTAL
Intervention: Methadone maintenance programs
Number of subjects: 2966

Group type: EXPERIMENTAL
Intervention: Outpatient drug-free programs
Number of subjects: 2966

Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 2966

Group type: EXPERIMENTAL
Intervention: Presence of dependence diagnosis
Number of subjects: 2966
Study: 8591712

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg daily for 12 weeks)
Number of subjects: 20
Study: 2612542

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam at 0.15 mg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rectal midazolam at 0.15 mg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral midazolam at 0.15 mg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral midazolam at 0.45 mg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral midazolam at 1 mg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All routes of administration
Number of subjects: 56
Study: 1037281

Group type: EXPERIMENTAL
Intervention: 200 mg mefexamide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 mg mefexamide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31622885

Group type: EXPERIMENTAL
Intervention: Allogeneic PRP treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 31438858

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow mononuclear cells (BMMNCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus conventional treatment
Number of subjects: 0
Study: 28786105

Group type: EXPERIMENTAL
Intervention: Low-dose 13-cis retinoic acid (7.5 mg or 10 mg) for 2 years
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 176
Study: 26418022

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg BID
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23237359

Group type: EXPERIMENTAL
Intervention: Alcohol-containing mouthwash (n = 38; 26% ethanol concentration)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Non-alcohol-containing mouthwash (n = 36)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 107
Study: 21788309

Group type: EXPERIMENTAL
Intervention: PIEB (10 mL every hour beginning 60 minutes after the initial dose)
Number of subjects: 145

Group type: COMPARATOR
Intervention: CEI (10 mL/h, beginning immediately after the initial dose)
Number of subjects: 145

Group type: COMPARATOR
Intervention: CEI
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: PIEB
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: PIEB and CEI
Number of subjects: 145
Study: 19363632

Group type: EXPERIMENTAL
Intervention: Head-shaking maneuver
Number of subjects: 103

Group type: COMPARATOR
Intervention: Modified Semont maneuver
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Switching maneuvers after initial non-response
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mastoid oscillation during Brandt-Daroff exercise
Number of subjects: 103
Study: 17088770

Group type: EXPERIMENTAL
Intervention: Auto-cross-linked hyaluronic acid gel (group A, 30 patients)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (group B, 24 patients)
Number of subjects: 54
Study: 15206994

Group type: EXPERIMENTAL
Intervention: RCTs reporting intention-to-treat analysis
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting description of withdrawals
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting description of adverse events
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting ethics review
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting informed consent
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting sources of funding
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting sequence generation
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting allocation concealment
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting use of restriction
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting description of blinding
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RCTs reporting flow diagrams of study participants
Number of subjects: 193
Study: 10997402

Group type: EXPERIMENTAL
Intervention: Three-times-daily indinavir (800 mg every 8 h or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Number of subjects: 521

Group type: COMPARATOR
Intervention: Two-times-daily indinavir (800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Number of subjects: 521
Study: 8769188

Group type: EXPERIMENTAL
Intervention: CyA‐ME (Neoral)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CyA‐GC
Number of subjects: 22
Study: 1591370

Group type: EXPERIMENTAL
Intervention: Protein A perfusion in cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein A-silica device in immune thrombocytopenia patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein A perfusion in cancer chemotherapy-related hemolytic-uremic syndrome
Number of subjects: 0
Study: 4054140

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg TID for 1 week
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg TID for 1 week
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 15
Study: 30336784

Group type: EXPERIMENTAL
Intervention: Specific Timely Appointments for Triage (STAT) model
Number of subjects: 3116

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 3116
Study: 28441294

Group type: EXPERIMENTAL
Intervention: Myofascial Release (MFR)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham MFR
Number of subjects: 54
Study: 26289684

Group type: EXPERIMENTAL
Intervention: Nurse-implemented transitional care (TC)
Number of subjects: 178
Study: 23904009

Group type: EXPERIMENTAL
Intervention: Modular treatment (N=15)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard treatment (N=13)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care (N=10)
Number of subjects: 38
Study: 21396214

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin/clavulanate 30 min before bronchoscopy
Number of subjects: 143

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 143
Study: 18510607

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 16514469

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI) for primary acquired cholesteatoma
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI) for residual cholesteatoma
Number of subjects: 100
Study: 14749008

Group type: EXPERIMENTAL
Intervention: Hypothermia group (HG); rectal temperature = 34.5 degrees C +/‐ 0.3 degrees C, nasopharyngeal temperature = 34.0 degrees C +/‐ 0.5 degrees C, n = 23
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normothermia group (NG); rectal temperature = 36.5 degrees C +/‐ 0.5 degrees C, n = 27
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypothermia group (HG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normothermia group (NG)
Number of subjects: 50
Study: 10750548

Group type: EXPERIMENTAL
Intervention: Stimulation condition (videotape presented)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No stimulation condition (no videotape)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-hyperactive children)
Number of subjects: 60
Study: 8682516

Group type: EXPERIMENTAL
Intervention: Sagittally symmetric postures
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rotated body 180 degrees to complete the task
Number of subjects: 10
Study: 1499246

Group type: EXPERIMENTAL
Intervention: PTFE‐type floss
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nylon waxed floss
Number of subjects: 60
Study: 6150050

Group type: EXPERIMENTAL
Intervention: C6/36 sham vaccine (subcutaneous administration)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: C6/36 sham vaccine (intraderma tests)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prausnitz‐Küstner test (using unheated sera)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prausnitz‐Küstner test (using heated sera)
Number of subjects: 12
Study: 3927959

Group type: EXPERIMENTAL
Intervention: Nicardipine 120 mg day-1
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31286497

Group type: EXPERIMENTAL
Intervention: High-status group
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Low-status group
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Third-party context (Study 1)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Random assignment to high-status or low-status group (Study 2)
Number of subjects: 273
Study: 29274727

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily)
Number of subjects: 3096

Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy (clopidogrel alone or combined aspirin and dipyridamole)
Number of subjects: 3096

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy
Number of subjects: 3096

Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy
Number of subjects: 3096
Study: 26760400

Group type: EXPERIMENTAL
Intervention: SBAR communication tool implementation
Number of subjects: 72

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 72
Study: 25676163

Group type: EXPERIMENTAL
Intervention: Multivitamin supplements
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 332

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 332
Study: 23715572

Group type: EXPERIMENTAL
Intervention: AS15 immunostimulant
Number of subjects: 75

Group type: COMPARATOR
Intervention: AS02B immunostimulant
Number of subjects: 75
Study: 20536472

Group type: EXPERIMENTAL
Intervention: Synthetic thymosin beta4 (Tbeta4) 42-1260 mg, administered intravenously, single dose and daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, administered intravenously, single dose and daily for 14 days
Number of subjects: 40
Study: 18685500

Group type: EXPERIMENTAL
Intervention: Allergen-free probiotics
Number of subjects: 0
Study: 16633359

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline rinses
Number of subjects: 40
Study: 14527812

Group type: EXPERIMENTAL
Intervention: Elderly men (mean age 67.7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Young men (mean age 23.6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 10839287

Group type: EXPERIMENTAL
Intervention: DBPT chemotherapy (dacarbazine, BCNU, cisplatin, and tamoxifen)
Number of subjects: 35

Group type: COMPARATOR
Intervention: DTIC chemotherapy
Number of subjects: 35
Study: 8971427

Group type: EXPERIMENTAL
Intervention: Captopril (2 x 25 mg day‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (1 x 100 mg day‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of captopril and ASA
Number of subjects: 13

Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 13
Study: 1378145

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 6502373

Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Axillary temperature measurement
Number of subjects: 100
Study: 30318561

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no IBPB)
Number of subjects: 152
Study: 26079743

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) for one month
Number of subjects: 4100

Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy for one month
Number of subjects: 4100

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy
Number of subjects: 4100

Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy
Number of subjects: 4100
Study: 23643328

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202
Study: 21287409

Group type: COMPARATOR
Intervention: ATRA alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ATRA switched to As(2)O(3) due to side effects of ATRA
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of ATRA and As(2)O(3)
Number of subjects: 37
Study: 19142569

Group type: EXPERIMENTAL
Intervention: High-protein soy-custard (25 En% protein/carbohydrate/fat)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-protein soy-custard (25 En%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal-protein soy-custard (10 En%)
Number of subjects: 25
Study: 16960167

Group type: EXPERIMENTAL
Intervention: Fish oil (17.6 mL/d, 1.8 g 20:5n-3, 3.0 g 22:6n-3, 5.9 g total n-3 fatty acids)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 26

Group type: COMPARATOR
Intervention: Corn oil (17.8 mL/d, 8.5 g 18:2n-6)
Number of subjects: 26
Study: 16451475

Group type: EXPERIMENTAL
Intervention: Mouthwash with 0.2% chlorhexidine and Anti Discoloration System (ADS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mouthwash with 0.2% chlorhexidine without Anti Discoloration System (ADS)
Number of subjects: 15
Study: 11722118

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiopental, propofol, and nimodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9930635

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FX) 20 mg/day (n=67)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Amitriptyline (AM) daily dose: 115+/‐39.2mg (n=75)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FX)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Amitriptyline (AM)
Number of subjects: 142